Shield Therapeutics (LON:STX)‘s stock had its “buy” rating reiterated by stock analysts at Peel Hunt in a report released on Wednesday, August 7th, ThisIsMoney.Co.Uk reports.
Separately, FinnCap restated a “corporate” rating on shares of Shield Therapeutics in a research note on Wednesday, August 7th.
Shares of Shield Therapeutics stock opened at GBX 176.85 ($2.31) on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.79 and a quick ratio of 4.57. The stock has a market cap of $208.01 million and a price-to-earnings ratio of 45.35. The firm’s 50-day moving average is GBX 135.50 and its 200 day moving average is GBX 95.94. Shield Therapeutics has a 1 year low of GBX 27 ($0.35) and a 1 year high of GBX 202 ($2.64).
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Read More: How to calculate compound interest
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.